Name: The Alamo Breast Cancer Foundation's 25th Alamo Advocate Program
Start: 06/12/2022 12:00 PM +00:00
End: 10/12/2022 01:00 AM +00:00

Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at <a href="https://www.gene.com">gene.com</a>.

Genentech

Exact Sciences

With more than 120 years of scientific expertise, Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology to contribute to the enrichment of quality of life around the world. In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. Learn more at <a href="https://daiichisankyo.us/">DaiichiSankyo.us. </a>

Daiichi-Sankyo

GE Healthcare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator. As the $17.7 billion healthcare business of GE (NYSE: GE), we operate at the center of the healthcare ecosystem, enabling precision health by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients&rsquo; demand for greater efficiency, access, and personalized medicine. Our products, services, and solutions enable clinicians to make more informed decisions quickly and efficiently, improving patient care from diagnosis to therapy to monitoring. We work to solve the greatest challenges in healthcare that patients and clinicians face today and in the future. Together, we are not only building a healthier future but living our purpose to create a world where healthcare has no limits.

GE Healthcare

Novartis

Eli Lilly

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. Sanofi recognizes the incredible burden cancer places on individuals and those who care for them. Their stories motivate and inspire us in our mission to develop novel treatment options, expand access to therapies, provide comprehensive patient support resources and work with patient organizations to fully understand the needs of those living with cancer. MBC Unfiltered focuses on the practical challenges of living with MBC, including the physical, emotional, and socioeconomic realities. It was developed for and with input from the community to share the real experiences of people living with MBC, providing perspectives about caregiver support, and connecting people to resources from MBC advocacy organizations around the world.

Sanofi Genezyme

Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies. We&rsquo;re driven by a singular mission&mdash;to make a difference for people impacted by cancer. As an industry leader in antibody&ndash;drug conjugate (ADC) technology, we pioneered the science of harnessing antibodies designed to deliver cell-killing agents to cancer cells. Three of our four approved medicines are built on this technology. We also focus our research efforts on novel targeted small molecule therapies. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents. Our Science

Seagen

*Breakfast will be provided at 7:30 a.m. CST*
About NBCC:&nbsp;
The National Breast Cancer Coalition (NBCC) has a unique history and an unmatched record of accomplishment in breast cancer. Since its inception in 1991, NBCC's mission has been to end breast cancer. NBCC has a long history of taking on big issues, challenging the status quo facing controversy head-on, and achieving success. NBCC links hundreds of organizations and tens of thousand*s of individuals from across the country into a dynamic, diverse coalition to achieve the organization's mission to end breast cancer and to give breast cancer a meaningful voice in Washington, D.C. and state capitals, in laboratories and health care institutions, and in local communities everywhere.
<a title="NBCC" href="https://www.stopbreastcancer.org/" target="_blank" rel="noopener">www.stopbreastcancer.org</a>
About the program:&nbsp;
The Future of HER2 Low Breast Cancer Dr. Nicholas McAndrew of the UCLA Geffen School of Medicine, will explore the unique characteristics of HER2 low breast cancer, the challenges involved in identifying HER2 low breast cancer, and what that means for the future of treatment. NBCC advocate, Beth Emery, will join him to provide an advocate perspective and facilitate a Q&amp;A session.&nbsp;

Dr. Nicholas McAndrew

Beth Emery, JD

Michelle Tregear

National Breast Cancer Coalition

Pre-recorded session with Dr. Sukh Makhnoon and Dr. Sanford Jeames.

Sukh Makhnoon

Sanford Jeames

Advocate Chat: Genetic Testing and Underserved Communites

Pre-recorded session with Dr. Fatima Cardoso and Christine Hodgdon.
&nbsp;

Agenda

Speakers34 Speakers

Dr. Nicholas McAndrew

Beth Emery, JD

Sukh Makhnoon

David Mankoff

Fatima Cardoso

Christine Hodgdon

Sanford Jeames

Laura Bowers

Keith Knutson

Bob Riter

Christine Miaskowski

Dr. Tatiana Prowell

Dr. Asma Dilawari

Dr. Bindu Lingam

Dr. Jennifer Gao

Dr. Preeti Narayan

Dr. Sebastian Winocour

Ashley Dedmon

Jeri Francoeur

Dr. Foluso Ademuyiwa

Dr. Steffi Oesterreich

Dr. Alastair Thompson

Dr. Jenny Chang

Dr. Debu Tripathy

Dr. Funmi Olopade

Dr. Virginia Kaklamani

Stephanie L. Goff

Michelle Tregear

Karen Russell

Amy Williams

Andrei Goga

Mary Jimenez

George Sledge

Daniel Belmares

Booth8 Booth